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down.”1 Health care, like politics, is local. Is it 
possible that what is cost-effective for one pro-
vider or consumer may not be true for another? 
How much of the problem is “provider” driven as 
compared with “consumer” driven, in which case 
the patient has little incentive to consider cost? 
Since medical egalitarianism does not endorse cost 
as the arbiter, who will make and enforce the 
decisions concerning cost? Is the provider free to 
consider scientific evidence when the trial bar 
can second-guess the process?
Although scientific advances look toward indi-
vidualized medicine, it appears that cost-account-
ing exalts the cookbook approach. Since a new 
system should be tested first on a small scale, 
perhaps any testing of the new and better health 
care system should be conducted first on its 
strongest proponents, the Congress.
Robert C. Kane, M.D.
901 S. Tamiami Trail  
Venice, FL
Weinstein MC, Skinner JA. Comparative effectiveness and 1. 
health care spending — implications for reform. N Engl J Med 
2010;362:460-5.
Pasireotide Alone or with Cabergoline and Ketoconazole  
in Cushing’s Disease
To the Editor: Cushing’s disease, which is caused 
by an adrenocorticotropin-secreting pituitary ad-
enoma, is associated with increased morbidity and 
mortality.1 Currently, there is no effective medi-
cal therapy for Cushing’s disease. However, recent 
studies identified the somatostatin-receptor sub-
type 5 and dopamine-receptor subtype 2 as po-
tential therapeutic targets in Cushing’s disease.2 
Pasireotide is a new somatostatin analogue that 
binds with high affinity to somatostatin-receptor 
subtypes 1, 2, and 3, and it especially has high-
affinity binding to somatostatin-receptor sub-
type 5.3 In a recent 15-day pilot study, pasireotide 
normalized the excretion of urinary free cortisol 
in 17% of patients with Cushing’s disease.4 Ca-
bergoline, a dopamine-receptor subtype 2 agonist, 
can also normalize levels of urinary free cortisol 
in Cushing’s disease, but this effect is often not 
maintained during prolonged treatment.5 Because 
the majority of adrenocorticotropin-secreting ad-
enomas simultaneously express somatostatin-
receptor subtype 5 and dopamine-receptor sub-
type 2,2 we hypothesized that pasireotide and 
dopamine-receptor subtype 2 agonists may have 
synergistic effects in the treatment of Cushing’s 
disease. Finally, ketoconazole suppresses cortisol 
production at the adrenal level through inhibition 
of steroidogenic enzymes.1 In a prospective, open-
label, multicenter trial, we used a stepwise ap-
proach for the medical treatment of Cushing’s 
disease, with pasireotide as the initial form of 
treatment and the sequential addition of cabergo-
line and low-dose ketoconazole.
Seventeen patients with Cushing’s disease 
(mean age, 45.7 years; 13 women) were included 
in an 80-day trial with normalization of levels of 
urinary free cortisol as the main outcome mea-
sure. All patients began treatment with 100 μg 
of pasireotide subcutaneously three times daily; 
this dose was increased to 250 μg subcutaneously 
three times daily at day 15 if the level of urinary 
free cortisol had not normalized. At day 28, ca-
bergoline was added to pasireotide at a dose of 
0.5 mg every other day (this dose was increased 
to 1.0 mg every other day after 5 days and 1.5 mg 
every other day after 10 days) if the level of uri-
nary free cortisol remained elevated. If the level 
of urinary free cortisol had not normalized at day 
60, ketoconazole was added at a dose of 200 mg 
thrice daily.
Pasireotide monotherapy induced sustained 
normalization of the level of urinary free corti-
sol in 5 of 17 patients (29%) (Fig. 1A). The addi-
tion of cabergoline normalized urinary free corti-
sol values in an additional 4 of 17 patients (24%). 
At day 60, a total of 8 of 17 patients (47%) still had 
elevated urinary free cortisol levels with pasireo-
tide–cabergoline combination therapy, although 
a trend toward normalization of levels of urinary 
free cortisol was observed in all but one patient, 
with a mean (±SE) decrease of 48±6% in the level 
of urinary free cortisol. The addition of low-dose 
ketoconazole induced biochemical remission in 
six of these eight patients at day 80, increasing 
the number of patients with a complete response 
to 88%. Figure 1B shows the effects of 28 days 
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of pasireotide monotherapy in relation to the se-
verity of hypercortisolism at baseline. In patients 
with mild hypercortisolism and those with se-
vere hypercortisolism, significant reductions in 
the level of urinary free cortisol of up to 67% of 
the baseline value were observed.
Along with the normalization of the level of 
urinary free cortisol, the clinical features of 
Cushing’s disease improved, including a de-
crease in body weight (−2.4±0.9 kg), waist cir-
cumference (−4.2±1.3 cm), systolic blood pres-
sure (−12±4 mm Hg), and diastolic blood 
pressure (−8±3 mm Hg). Adverse events included 
disturbance of glucose homeostasis (glycated 
hemoglobin level, 5.8±0.2% to 6.7±0.3%; P<0.01) 
and a decrease in levels of serum type I insulin-
like growth factor to below the lower limit of the 
normal range in 9 of 17 patients.
Thus, stepwise medical therapy for Cushing’s 
disease with the use of three drugs that differ-
entially target somatostatin-receptor subtype 5 
and dopamine-receptor subtype 2 receptors in 
the adrenocorticotropin-secreting adenoma and 
steroidogenic enzymes in the adrenal cortex re-
sulted in biochemical control in nearly 90% of 
patients. 
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Figure 1. Levels of Urinary Free Cortisol after Treatment for Cushing’s  
Disease.
Panel A shows mean levels of urinary free cortisol in five patients treated 
with pasireotide monotherapy, four patients treated with combination ther-
apy with pasireotide plus cabergoline, and eight patients treated with pasireo-
tide plus cabergoline and ketoconazole. Cabergoline was added to pasireotide 
if the level of urinary free cortisol had not normalized at day 28. Ketoconazole 
was added to pasireotide and cabergoline at day 60 if the patient had per-
sistent hypercortisolism. The upper limit of the normal range is indicated 
by the dashed line. I bars indicate the standard errors. Panel B shows the 
percent change from baseline in urinary free cortisol levels in all patients 
after pasireotide monotherapy at day 28 in relation to the severity of hyper-
cortisolism before treatment. Hypercortisolism, measured according to the 
urinary free cortisol level, was classified as mild (1 to <2 times the upper 
limit of the normal range), moderate (2 to <4 times the upper limit of the 
normal range), or severe (4 to 6 times the upper limit of the normal range). 
In four patients, the urinary free cortisol level decreased by 50 to 75% from 
baseline, and in seven patients, this level decreased by 25 to 50% from 
baseline. Patients in whom urinary free cortisol levels normalized during 
pasireotide monotherapy had a baseline urinary free cortisol level of one to 
two times the upper limit of the normal range (bars with  asterisks).
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Atypical Femoral Fractures and Bisphosphonate Use
To the Editor: Since 2007, there have been sev-
eral reports suggesting a potential association 
between the use of bisphosphonates and the oc-
currence of subtrochanteric or so-called atypical 
femoral fracture.1-4 However, a recent registry-
based cross-sectional study did not show a great-
er frequency of such fractures in patients receiv-
ing alendronate.5 Thus, the association between 
atypical femoral fractures and bisphosphonate use 
remains an open issue.
We reviewed 152 femoral fractures (not includ-
ing hip) that occurred in 152 patients who were 
admitted to a tertiary center during a 60-month 
period from June 2003 through May 2008. The 
mean (±SD) age of the patients was 78±5 years, 
and 132 of the patients were women. A senior 
orthopedic surgeon who was unaware of the 
patients’ baseline characteristics and medication 
use reviewed the fracture radiographs of every 
patient in random sequence on two separate oc-
casions (Cohen’s κ = 0.8), identifying those frac-
tures that fit the criteria for an atypical fracture 
(i.e., a lateral transverse or <30-degree oblique 
fracture line in an area of cortical thickening with 
a medial unicortical beak), as described previ-
ously. 3,4 
Twenty of the 152 fractures were classified as 
atypical. After unblinding of the database, 17 pa-
tients in this group were found to be receiving 
current oral bisphosphonate treatment. Of these 
patients, 15 were taking alendronate (mean treat-
ment duration, 5.1 years), and 2 were taking ris-
edronate (mean treatment duration, 3 years). Of 
the 132 patients whose radiographs did not ful-
fill the criteria for atypical fracture, 2 patients 
(1.5%) were taking alendronate, and 1 patient was 
taking risedronate (0.8%), with mean treatment 
durations of 3.5 years and 1 year, respectively.
The atypical fracture pattern appeared to be 
96.7% specific to patients receiving bisphospho-
nates.
Several additional risk factors were associated 
with atypical femur fracture. These included a 
history of low-energy fracture (odds ratio, 3.2; 
95% confidence interval [CI], 2.1 to 17.1; 
P<0.001), the use of glucocorticoid therapy for 
more than 6 months (odds ratio, 5.2; 95% CI, 
1.3 to 31.0; P = 0.01), active rheumatoid arthritis 
(odds ratio, 16.5; 95% CI, 1.4 to 142.3; P<0.001), 
and a level of serum 25-hydroxyvitamin D of less 
than 16 ng per milliliter (40 nmol per liter) 
(odds ratio, 3.5; 95% CI, 1.7 to 18.7; P<0.001).
Although there is an association between 
atypical subtrochanteric femur fracture and oral 
bisphosphonate use, clinicians should remember 
that bisphosphonates significantly reduce the 
risk of fragility fractures in patients with osteo-
porosis and that overall the antifracture effects 
of bisphosphonates far outweigh their potential 
risks.
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